A Phase 1 Study of ABT-869 in Subjects With Solid Tumors

Phase 1 Completed 18 enrolled AbbVie

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the pharmacokinetics, safety and tolerability of ABT-869 in Japanese patients with solid tumors up to the Recommended Phase Two Dose that was determined in a previous the M04-710 study.

Timeline

Start: 2008-09
Primary completion: 2012-06
Completion: 2012-06

Publications

Results Asahina H, Tamura Y, Nokihara H, Yamamoto N, Seki Y, Shibata T, Goto Y, Tanioka M, Yamada Y, Coates A, Chiu YL, Li X, Pradhan R, Ansell PJ, McKeegan EM, McKee MD, Carlson DM, Tamura T. An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemother Pharmacol. 2012 Jun;69(6):1477-86. doi: 10.1007/s00280-012-1846-6. Epub 2012 Mar 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ABT-869	Unknown	0.05 mg/kg	Oral
Subject	ABT-869	Unknown	0.1 mg/kg	Oral
Subject	ABT-869	Unknown	0.2 mg/kg	Oral
Subject	ABT-869	Unknown	0.25 mg/kg	Oral

A Phase 1 Study of ABT-869 in Subjects With Solid Tumors

Summary

Timeline

Publications

Drugs

Indications